The cancer community is deeply concerned about the unintended consequences of the current wording of the European Union (EU) draft Regulation on Data Protection, which may challenge the survival of retrospective clinical research, biobanking, and population-based cancer registries in the EU. This directive could negatively affect Europe's competitiveness in cancer research.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
General data protection regulations (2018) and clinical research: perspectives of patients and doctors in an Irish university teaching hospital
Irish Journal of Medical Science (1971 -) Open Access 30 September 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
De Angelis, R. et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 15, 23–34 (2013).
Speirs, V. & Morgan, A. Breast cancer: investment biobanking—increased returns from tissue samples. Nat. Rev. Clin. Oncol. 10, 128–129 (2013).
Casali, P. Risks of the new EU data protection regulation: an ESMO position paper endorsed by the European oncology community. Ann. Oncol. 25, 1458–1461 (2014).
Rosmarin, D. et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J. Clin. Oncol. 32, 1031–1039 (2014).
Church, D. et al. 'Toxgnostics': an unmet need in cancer medicine. Nat. Rev. Cancer 14, 440–445 (2014).
Salazar, R. et al. A gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol. 29, 17–24 (2011).
Palles, C. et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45, 136–144 (2012).
Quirke, P. et al. Value of mismatch repair, KRAS and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29, 1261–1270 (2011).
Gray, R. G. et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J. Clin. Oncol. 29, 4611–4619 (2011).
Human Tissue Authority. Human Tissue Act 2004 [online], (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Kerr, D. EU data protection regulation—harming cancer research. Nat Rev Clin Oncol 11, 563–564 (2014). https://doi.org/10.1038/nrclinonc.2014.148
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.148
This article is cited by
-
General data protection regulations (2018) and clinical research: perspectives of patients and doctors in an Irish university teaching hospital
Irish Journal of Medical Science (1971 -) (2022)
-
Big Data in medical research and EU data protection law: challenges to the consent or anonymise approach
European Journal of Human Genetics (2016)
